The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
Kassidy BeyerlinRachel JimenezMark ZangardiGeoffrey G FellChristine EdmondsAndrew JohnsonVeerle BossuytMichelle SpechtTherese M MulveyBeverly MoyLeif W EllisenSteven J IsakoffAditya BardiaLaura M SpringPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Tolerability was poor overall compared to the CREATE-X cohort. Administering adjuvant capecitabine for TNBC patients with residual disease in the United States is challenging given differences in tolerability. More research is needed to understand how poor tolerability will affect the efficacy of this approach in the US population.